Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study

Autor: Ozden Ozdemir Baser, Salih Suha Koparal, Dilek Berker, Derya Köseoğlu
Jazyk: angličtina
Rok vydání: 2021
Předmět:
nonalcoholic fatty liver disease
Adult
Male
medicine.medical_specialty
Waist
Subcutaneous Fat
Intra-Abdominal Fat
Gastroenterology
Carotid Intima-Media Thickness
Article
Body Mass Index
Non-alcoholic Fatty Liver Disease
Risk Factors
Internal medicine
Nonalcoholic fatty liver disease
Carotid intima media thickness
medicine
Humans
visceral fat volume
cardiovascular diseases
Obesity
Prospective Studies
Prospective cohort study
medicine.diagnostic_test
business.industry
Type 2 Diabetes Mellitus
nutritional and metabolic diseases
General Medicine
Middle Aged
medicine.disease
Lipids
subcutaneous fat thickness
hsCRP
lipid profile
C-Reactive Protein
Intima-media thickness
Diabetes Mellitus
Type 2
Liver
Cardiovascular Diseases
Obesity
Abdominal
Exenatide
Female
Anti-Obesity Agents
Lipid profile
business
Body mass index
medicine.drug
Zdroj: Turkish Journal of Medical Sciences
ISSN: 1303-6165
1300-0144
Popis: Background/aim The aim of this study was to evaluate the effects of a 6-month treatment regimen with exenatide on the lipid profile, high-sensitivity C-reactive protein (hsCRP), carotid intima media thickness (CIMT), visceral adiposity, and nonalcoholic fatty liver disease (NAFLD), all of which are important cardiovascular risk factors. Materials and methods This study included 45 obese patients with type 2 diabetes mellitus (T2DM). Baseline clinical findings, laboratory parameters, and ultrasonography findings were recorded. An exenatide recipe was given twice daily to the patients and, after 6 months of therapy, the same variables were compared. The compared parameters were lipid profiles, hsCRP, aspartat aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, liver craniocaudal diameter, visceral fat volume, subcutaneous fat thickness, and CIMT. Liver diameter, visceral fat volume, subcutaneous fat thickness, and CIMT were measured by ultrasonography. Results After therapy, statistically significant improvements were achieved in lipid profile, hsCRP, liver enzymes, body mass index, and waist and hip circumferences. Also, statistically significant decreases were obtained in liver craniocaudal diameter, subcutaneous fat thickness, visceral fat volume, and CIMT. The reduction of CIMT and liver diameter were not correlated with BMI and HbA1c reduction. Conclusion This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant decrease in liver diameter. These findings support the use of exenatide in patients with NAFLD and T2DM. Additionally, this study showed that exenatide treatment given twice daily reduces CIMT in obese T2DM patients.
Databáze: OpenAIRE
Externí odkaz: